In comparison, even the current PARP inhibitor maintenance therapy for all ovarian cancers prolongs median survival by only 12.9 months, reduces the risk of death by 26%, and improves 5-year survival by 9%24 (SOLO2)25. In this way, the benefit of SLC11A2 as a therapeutic target is considerable. This evidence concerns the gene SLC11A2 and ovarian cancer.